Home›Clinical trials›LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosi
Enrolling now · NCT06632444

A study testing whether a new weekly shot from Boehringer Ingelheim, survodutide, can improve fatty liver disease.

What this means for you

Who can join
Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).
What you take
survodutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 7.3 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 3Sponsor Boehringer IngelheimDrug survodutideClass GLP-1/glucagonSites 165 USEnrollment target 1,800

What this study is for

Primary condition: Metabolic Dysfunction Associated Steatohepatitis (MASH). Also studied in: Liver Fibrosis.

Full scientific study title: LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosi.

Who can join

Age18 and upSexAny

Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis). A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Male or female participants >=18 years (or who are of legal age in countries where that is greater than 18 years) of age at time of consent
  • Diagnosis of MASH (non-alcoholic fatty liver disease (NAFLD)) activity score [NAS] >=4
  • Stable body weight defined as less than 5% self-reported change in body weight 3 months prior to the screening or during the period between the historical biopsy and randomisation, if a historical biopsy is used
  • Be willing to maintain a stable diet and physical activity levels throughout the entire trial Further apply

Key exclusion criteria

  • Any of the following liver laboratory test abnormalities at screening:
  • Serum AST and/or alanine aminotransferase (ALT) elevation >=5x upper limit of normal (ULN)
  • Platelet count <140 000/mm^3 (<140 GI/L)
  • Alkaline phosphatase >2x upper limit of normal (ULN)
  • Abnormal synthetic liver function as defined by screening central laboratory evaluation:

Where this study is enrolling

This trial has 165 sites across 30 states. Contact a site coordinator directly to start screening.

Alabama1 site
Arizona5 sites
California25 sites
Colorado2 sites
Connecticut2 sites
Florida37 sites
Georgia2 sites
Indiana2 sites
Iowa2 sites
Kansas2 sites
Louisiana3 sites
Maryland1 site
Massachusetts1 site
Michigan2 sites
Minnesota1 site
Mississippi1 site
Missouri3 sites
Nebraska1 site
Nevada3 sites
New Jersey1 site
New York4 sites
North Carolina5 sites
Ohio4 sites
Oklahoma1 site
Pennsylvania5 sites
South Carolina3 sites
Tennessee3 sites
Texas38 sites
Virginia3 sites
Washington2 sites

Timeline

Started enrolling: 2024-09-17. Expected completion: 2031-12-27. Last updated on ClinicalTrials.gov: 2026-05-28.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.